

Applicant : Svetomir N. Markovic
Serial No. : 09/187,385
Filed : November 6, 1998
Page : 2 of 5

Attorney's Docket No.: 07039-119001

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1-29. (Canceled)

30. (Currently Amended) ~~The method of claim 27, said method further comprising administering said immunostimulatory dosage~~ A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:
 a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;
 b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage increases natural killer lymphocyte cytotoxicity at least about 75% above said baseline natural killer lymphocyte cytotoxicity; and
 c) surgically resecting said malignant tumor,
 wherein said immunostimulatory dosage is administered to said patient for about five days prior to resecting said malignant tumor.

31-35. (Canceled)

36. (Currently Amended) ~~The method of claim 27,~~ A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:
 a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;
 b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage increases natural killer lymphocyte cytotoxicity at least about 75% above said baseline natural killer lymphocyte cytotoxicity; and
 c) surgically resecting said malignant tumor,
 wherein said malignant tumor is an early-stage solid tumor.

Applicant : Svetomir N. Markovic
Serial No. : 09/187,385
Filed : November 6, 1998
Page : 3 of 5

Attorney's Docket No.: 07039-119001

37. (Currently Amended) ~~The method of claim 27,~~ A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:
- a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;
 - b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage increases natural killer lymphocyte cytotoxicity at least about 75% above said baseline natural killer lymphocyte cytotoxicity; and
 - c) surgically resecting said malignant tumor,
- wherein said malignant tumor is a melanoma.
- 38-56. (Canceled)